Clinical Trial Update: Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)

View source ↗

Summary

Clinical trial update for TALENP002 triple therapy for intermediate-advanced hepatocellular carcinoma with bile duct tumor thrombosis; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• TALENP002

Snippet

Sponsor: Fujian Provincial Hospital | Conditions: Hepatocellular Carcinoma | Status: RECRUITING